290 related articles for article (PubMed ID: 28686809)
1. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
2. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
3. Still Elegantly Muddling Through? NICE and Uncertainty in Decision Making About the Rationing of Expensive Medicines in England.
Calnan M; Hashem F; Brown P
Int J Health Serv; 2017 Jul; 47(3):571-594. PubMed ID: 28114872
[TBL] [Abstract][Full Text] [Related]
4. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
5. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
6. It's not evidence, it's insight: bringing patients' perspectives into health technology appraisal at NICE.
Staley K; Doherty C
Res Involv Engagem; 2016; 2():4. PubMed ID: 29062505
[TBL] [Abstract][Full Text] [Related]
7. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
9. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
10. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
11. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
Dietrich ES
Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
[TBL] [Abstract][Full Text] [Related]
12. Assessment of quality of data submitted for NICE technology appraisals over two decades.
Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
[TBL] [Abstract][Full Text] [Related]
13. The impact of rarity in NICE's health technology appraisals.
Clarke S; Ellis M; Brownrigg J
Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
[TBL] [Abstract][Full Text] [Related]
14. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
15. NICE's use of cost effectiveness as an exemplar of a deliberative process.
Culyer AJ
Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
[TBL] [Abstract][Full Text] [Related]
16. Getting their say, or getting their way? Has participation strengthened the patient "voice" in the National Institute for Clinical Excellence?
Quennell P
J Manag Med; 2001; 15(3):202-19. PubMed ID: 11547580
[TBL] [Abstract][Full Text] [Related]
17. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
Brown P; Calnan M
Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
[TBL] [Abstract][Full Text] [Related]
18. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
19. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler E; Papaioannou D; Boland A; Dickson R
Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
[TBL] [Abstract][Full Text] [Related]
20. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
